Alloy Therapeutics and Sanofi Partner to Advance CNS Therapeutics Using Novel Antisense Platform
Alloy Therapeutics Inc., a biotechnology ecosystem company focused on democratizing access to cutting-edge drug discovery technologies, announced a collaboration and license agreement with Sanofi for the use of its proprietary AntiClastic Antisense Platform to target a central nervous system (CNS) indication. The collaboration reflects a mutual commitment to developing innovative therapies for CNS disorders. Alloy’s AntiClastic Antisense Platform offers a transformative approach to antisense therapeutics, enabling precise targeting of intracellular disease pathways at the RNA level. The platform addresses challenges associated with the therapeutic index of current antisense chemistries, unlocking new opportunities for therapeutic development. This groundbreaking technology, launched by Alloy in 2023, is based on intellectual property exclusively licensed from Arnay Sciences, developed by Sudhir Agrawal, and features a novel spatial conformation of oligonucleotides.
Alloy Therapeutics and Sanofi Partner to Advance CNS Therapeutics Using Novel Antisense Platform